The role of electrogastrography and gastrointestinal hormones in chemotherapy-related dyspeptic symptoms
Authors:
- 26 December 2005
- journal article
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 40 (12) , 1107-1115
Abstract
The aim of this study was to investigate the relationship among motility disorders, dyspeptic symptoms, and plasma levels of gastrointestinal hormones in cancer patients who were well controlled for post-chemotherapy emesis. Twenty-five cancer patients treated with standard dosages of antiemetics and chemotherapies completed the study. Gastrointestinal symptoms were investigated by detailed questionnaire and visual analog score. Motility was investigated by cutaneous electrogastrography, and by blood levels of gastrin, serotonin, vasopressin, and substance P, before and 7 days after chemotherapy. Before chemotherapy, no patient complained of dyspeptic symptoms, and no differences in electrogastrography (EGG) or in circulating peptide levels were found between patients who developed dyspepsia and those who did not. After chemotherapy, 13 patients suffered from dysmotility-like symptoms (total symptom score, 11.5 [2.5–37.9]; median value and 5th–95th percentiles), with susceptibility to nausea, early satiety, and postprandial fullness being the major complaints. As regards EGG parameters, a significant reduction (P = 0.04; Mann-Whitney test) in the normal slow-wave percentage and significantly increased tachygastria percentage were found in dyspeptic patients compared with symptom-free patients. The tachygastria percentage was significantly associated with susceptibility to nausea score, in a non-linear fashion (R 2 = 0.37). Dyspeptic patients showed lower levels of substance P and gastrin than patients who were not dyspeptic, but this difference had no clinical significance for dyspepsia. Chemotherapy may induce upper gastrointestinal symptoms suggestive of motility disorders. These dyspeptic symptoms were associated with EGG alterations, but not with variations in circulating peptides. Other hormones or pathophysiological factors, not considered in the present work, could be actively involved in these dyspeptic symptoms.Keywords
This publication has 36 references indexed in Scilit:
- The Ups and Downs of Novel Antiemetic Drugs, Part 2The Journal of Clinical Psychiatry, 2003
- Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonistsEuropean Journal of Cancer, 2003
- Cancer and chemotherapy-related upper gastrointestinal symptoms: the role of abnormal gastric motor function and its evaluation in cancer patientsSupportive Care in Cancer, 2002
- Functional Dyspepsia Symptoms, Gastric Emptying and Satiety Provocative Test: Analysis of RelationshipsScandinavian Journal of Gastroenterology, 2001
- Potential of Substance P Antagonists as AntiemeticsDrugs, 2000
- New perspectives in antiemetic treatmentSupportive Care in Cancer, 1996
- Can transcutaneous recordings detect gastric electrical abnormalities?Gut, 1991
- Electrogastrography: Clinical ApplicationsScandinavian Journal of Gastroenterology, 1989
- Human electrogastrogramsDigestive Diseases and Sciences, 1986
- What is measured in electrogastrography?Digestive Diseases and Sciences, 1980